Your session is about to expire
← Back to Search
risankizumab SC for Ulcerative Colitis
Study Summary
This trial is testing a new medication for ulcerative colitis. The first part is to see if it works and what the best dose is. The second part is to see if it works better than a placebo.
- Ulcerative Colitis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 618 Patients • NCT03104413Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does this experimental treatment only cater to young adults?
"The minimum age for this clinical trial is 16 and the maximum age is 80, as specified in the eligibility requirements."
How can I qualify to take part in this clinical research project?
"This trial is looking for 1554 participants with ulcerative colitis between the ages of 16 and 80. Females must be postmenopausal for more than 1 year or surgically sterile or practicing specific forms of birth control, and males or females must be aged 18 to 80 years at the Baseline Visit. Subjects 16 to < 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit may also be eligible. Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to Baseline, active UC as assessed by Adapted Mayo Score and Endoscopic Subscore"
How is risankizumab SC most often employed?
"risankizumab SC is indicated for use in patients that might respond to phototherapy, as well as those suffering from moderate to severe plaque psoriasis, who have an inadequate response or intolerance to disease-modifying antirheumatic drugs, and dental plaque."
How many people can join this test group and still have it be considered reliable?
"This trial is no longer recruiting patients. The study was posted on 3/7/2018 and was last edited on 8/29/2022. For those still exploring their options, there are 425 other studies for colitis, ulcerative and 16 for risankizumab SC that are actively recruiting patients."
Are there other instances where risankizumab SC has been used in a medical study?
"Risankizumab SC is being studied in 16 different ongoing clinical trials, 13 of which are in Phase 3. Many of the research sites for risankizumab SC are located in Gdansk, Pomorskie, but there are 3193 total locations for these trials."
Are patients still being accepted for participation in this research project?
"This particular trial, which was last updated on 8/29/2022, is not actively recruiting patients according to the latest information from clinicaltrials.gov. However, there are 441 other medical studies that are actively looking for participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger